SCHEMBL5127340

SCHEMBL5127340

CCOC(=O)C(=Cc1ccccc1Br)NC=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
POLB P06746 2/20 0.45
PLIN1 O60240 1/20 0.45
PLIN5 Q00G26 1/20 0.45
ABHD5 Q8WTS1 1/20 0.45
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
S1PR4 O95977 1/20 0.41
S1PR1 P21453 1/20 0.41
MAPK1 P28482 1/20 0.41
GAA P10253 3/20 0.40
TDP1 Q9NUW8 1/20 0.39
DHODH Q02127 1/20 0.39
GPR35 Q9HC97 1/20 0.38
HSD11B1 P28845 1/20 0.37
F2R P25116 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127336 1.00 MEN1 (0.45) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL5130216 0.85 LMNA (0.44) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL5130213 0.85 LMNA (0.44) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL3494802 0.81 MEN1 (0.64) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL3494804 0.81 MEN1 (0.64) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL6220710 0.81 MAPT (0.50) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL8432135 0.81 MEN1 (0.66) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL6220713 0.81 MAPT (0.50) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL1676566 0.80 MEN1 (0.53) MEN1KMT2ALMNAMAPTPOLB
SCHEMBL28562987 0.80 MAPT (0.49) MEN1KMT2ALMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF MYD88, TLR7, MAVS MEN1 3676/4885KMT2A 1184/4885LMNA 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.